Xeris Biopharma Reports Fourth Quarter and Full-year 2021 Financial Results and Recent Events
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Xeris Pharmaceuticals Inc. (XERS) Misses Q4 EPS by 18c
March 10, 2022 7:02 AM ESTXeris Pharmaceuticals Inc. (NASDAQ: XERS) reported Q4 EPS of ($0.42), $0.18 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $21.43 million versus the consensus estimate of $18.9 million.
The Company is providing the following financial guidance:
Net product revenue of $105 million to $120... More